New Evidence for Beneficial Effects of Statins Unrelated to Lipid Lowering
2001; Lippincott Williams & Wilkins; Volume: 21; Issue: 1 Linguagem: Inglês
10.1161/01.atv.21.1.3
ISSN1524-4636
Autores Tópico(s)Computational Drug Discovery Methods
ResumoHomeArteriosclerosis, Thrombosis, and Vascular BiologyVol. 21, No. 1New Evidence for Beneficial Effects of Statins Unrelated to Lipid Lowering Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBNew Evidence for Beneficial Effects of Statins Unrelated to Lipid Lowering Wulf Palinsk Wulf PalinskWulf Palinsk From the Department of Medicine, University of California, San Diego. Originally published1 Jan 2001https://doi.org/10.1161/01.ATV.21.1.3Arteriosclerosis, Thrombosis, and Vascular Biology. 2001;21:3–5Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (statins) constitute the single most powerful class of hypolipidemic drugs currently available. Their efficacy in reducing coronary morbidity and mortality has been established by several large secondary and primary intervention trials (reviewed in Reference 11 ). Remarkably, in some of these trials, survival curves began to diverge within a relatively short period, presumably too short to achieve a significant reduction of preexisting atheroma2 or to prevent progression of lesions to clinically relevant stages. This suggests that effects of statins other than lesion regression contribute to the rapid reduction of coronary symptoms.During the past several years, numerous additional effects of statins on vascular cells have been identified that could modulate atherogenesis, plaque rupture, or thrombosis. Some of these appear to be independent of cholesterol lowering.34 For example, statins upregulate nitric oxide (NO) expression by interfering with the posttranscriptional regulation of endothelial NO synthase (eNOS).56 Evidence for the importance of this mechanism in vivo was provided by the observation that statins inhibit ischemic cerebral stroke induced by occlusion of the middle cerebral artery in normal but not in eNOS-deficient mice.7 Other potentially protective effects of statins on endothelial cells include an increased fibrinolytic activity through enhanced expression of tissue plasminogen activator and platelet activator inhibitor-1.8 In smooth muscle cell cultures, statins inhibit proliferation9 and stimulate apoptosis.10 Monocyte recruitment into the vascular intima in response to inflammatory cytokines may also be affected by statins, which inhibit the expression of monocyte chemotactic protein-1 by stimulated peripheral blood monocytes and endothelial cells.11Such pleiotropic effects of statins are not altogether surprising. In addition to reducing cholesterol synthesis (and plasma cholesterol levels by compensatory upregulation of LDL receptors), HMG-CoA reductase inhibitors decrease formation of isoprenylated and geranylgeranylated proteins through the mevalonate pathway. The role of protein lipidation in cell signaling is increasingly recognized,1213 and many of the cholesterol-independent effects referred to above were reversible by addition of geranylgeranyl or farnesyl pyrophosphate.578910 However, it is difficult to estimate the contribution of specific cholesterol-independent effects of statins to the overall reduction of coronary morbidity and mortality because of the marked hypocholesterolemic effects in most human trials and animal studies. Cholesterol lowering—not only by statins but also by dietary means or other drugs—stabilizes plaques via a number of different mechanisms.14 Conversely, hypercholesterolemia—or the enhanced lipid peroxidation that ensues—activates many of the same pathogenic mechanisms that are attenuated by statins via cholesterol-independent pathways. Classic examples include monocyte chemotactic protein-1 expression, which is regulated by the oxidation-sensitive nuclear factor κB pathway,15 and apoptotic signaling.16 Vascular reactivity, too, may be influenced by the cholesterol-lowering effect of statins. Thus, synergisms of indirect effects resulting from cholesterol lowering and cholesterol-independent cellular effects of statins are likely to exist.Nevertheless, increasing evidence suggests that the anti-inflammatory effects of statins play an important role in attenuating atherosclerosis and other inflammatory processes. A significant reduction of cardiac rejection, lower incidence of vasculopathies, less intimal thickening, and increased survival were observed in cardiac transplantation patients treated with pravastatin or simvastatin.1718 Neointimal inflammation was also reduced in a rabbit model.19 Again, this was associated with a significant reduction in plasma cholesterol. Other indications for an anti-inflammatory effect are provided by the reduction of C-reactive protein in a randomly selected subgroup of subjects from the Cholesterol and Recurrent Events (CARE) study.20 However, neither the mechanism responsible nor the independence of this effect from the cholesterol-lowering effect of statins have been established.In the current issue of Arteriosclerosis, Thrombosis, and Vascular Biology, Sparrow and colleagues21 provide compelling in vivo evidence for direct, cholesterol-independent inhibition of both acute and chronic inflammatory conditions. Using an established model of acute inflammation characterized by infiltration of polymorphonuclear leukocytes, ie, the plantar injection of a sterile, carrageenan-containing solution, they demonstrated a significant reduction of edema formation in C57BL/6NT mice orally treated with simvastatin 1 hour before carrageenan injection. The effect was dose dependant and comparable to that achieved with indomethacin. Both treated and control mice had normal cholesterol levels, and the short time interval in any case rules out hypocholesterolemic effects. Similar treatment 24 hours before plantar injection of the irritant had no effect. The authors then tested the effect of simvastatin treatment on atherosclerosis in apolipoprotein E–deficient (apoE–/–) mice. Previous studies had shown that inhibition of HMG-CoA reductase does not significantly lower cholesterol levels in mice,22 and this was also true in apoE–/– mice fed a diet containing 0.15% cholesterol. In the absence of a significant hypocholesterolemic effect, treatment of 16- to 20-week-old mice with 100 mg simvastatin/kg body weight for only 6 weeks resulted in a significant reduction of the aortic content in total and free cholesterol and cholesteryl esters, compared with controls. In a separate experiment, carrier-treated control animals showed a marked increase in aortic cholesterol, compared with animals killed at baseline, and simvastatin reduced this by 66% to 77%. Given that the aortic cholesterol content is generally correlated with surface or cross-sectional measures of atherosclerosis, these date can be considered to provide the first evidence for a significant reduction of atherosclerosis by statins through a mechanism(s) independent of cholesterol lowering. Most important, this effect was evident in a model with extensive preexisting atherosclerotic lesions and occurred within a remarkably short time.To date, little is known about the anti-inflammatory effects of statins in vivo. The study by Sparrow and colleagues21 unfortunately did not investigate the effects of statins on the presence of inflammatory cells or cytokine expression in lesions (with the exception of intimal macrophages) and thus cannot shed light on the mechanism(s) responsible for the reduction of atherosclerosis. Previous in vitro studies, however, have identified a number of candidates. In addition to reducing endothelial leukocyte interactions1123 and protecting against neutrophil-induced ischemic reperfusion injury,24 at least 1 statin (lovastatin) inhibits expression of inducible NO synthase and the proinflammatory cytokines tumor necrosis factor-α, interleukin (IL)-1β, and IL-6 in macrophages.25 Similar effects were noted in rat astrocytes and microglial cells,24 and lovastatin treatment significantly improved survival in a rat model of experimental allergic encephalomyelitis.26 IL-8 and MCP-1 secretion of Chlamydia pneumoniae–infected human macrophages was also attenuated by statins.27 In addition, a recent report suggests that lipophilic statins inhibit proinflammatory cytokines IL-1β, IL-6, and cyclooxygenase-2 by upregulating the peroxisome proliferator activated receptor-α (PPARα) in endothelial cells.28 A marked antiatherogenic effect resulting from the downregulation of several proinflammatory genes induced by synthetic PPAR-γ ligands has recently been demonstrated,29 but analogous evidence for PPAR-α ligands is still outstanding.Finally, an important new role for statins in immunosuppression was just reported by the group of Dr François Mach.30 This elegant study demonstrated that statins inhibit the expression of major histocompatibility class II (MHC II) antigens by primary human macrophages and endothelial cells in response to interferon-γ (IFN-γ). The effect was dose dependent, exerted to various extents by different statins, and limited to cells that express MHC II only in response to IFN-γ stimulation. In contrast, "professional" antigen-presenting cells constitutively expressing MHC II, such as dendritic cells and B lymphocytes, were not inhibited, and neither was MHC I expression. Inhibition of MHC II resulted from reduced activation of the inducible promoter IV of the transactivator CIITA.3031 Because expression of MHC II molecules plays an important role in the activation of T-cell subpopulations (T-helper cells), the immunosuppressive activity of statins may greatly contribute to the beneficial effect of statins in cardiac transplant patients.3032 Although an indication of statins as immunosuppressors for chronic inflammatory conditions will require confirmation by in vivo studies, in vivo evidence for a beneficial role of other forms of specific immunomodulation in atherosclerosis already exists (reviewed in Reference 3333 ). Inhibition of MHC II expression is unlikely to account for the protective role of statins in the acute inflammatory response observed by Sparrow et al,21 but it would be worth testing its potential involvement in the reduction of atherosclerosis in their model and over longer time periods.The cholesterol-independent effects of statins appear to be well documented in vitro and a growing number of experimental models. Their relevance to humans, however, remains to be established, particularly in view of the high doses of statins required to achieve some of these effects.FootnotesCorrespondence to Wulf Palinski, MD, University of California, San Diego, Department of Medicine, 0682, 9500 Gilman Dr, MTF 110, La Jolla, CA 92093-0682. E-mail [email protected] References 1 Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation.2000; 101:207–223.LinkGoogle Scholar2 Blankenhorn DH, Hodis HN. George Lyman Duff memorial lecture: arterial imaging and atherosclerosis reversal. Arterioscler Thromb.1994; 14:177–192.CrossrefMedlineGoogle Scholar3 Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA.1998; 279:1643–1650.CrossrefMedlineGoogle Scholar4 Faggiotto A, Paoletti R. State-of-the-art lecture: statins and blockers of the renin-angiotensin system: vascular protection beyond their primary mode of action. Hypertension.1999; 34:987–996.CrossrefMedlineGoogle Scholar5 Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation.1998; 97:1129–1135.CrossrefMedlineGoogle Scholar6 Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem.1998; 273:24266–24271.CrossrefMedlineGoogle Scholar7 Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, Liao JK. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA.1998; 95:8880–8885.Google Scholar8 Essig M, Nguyen G, Prie D, Escoubet B, Sraer JD, Friedlander G. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells: role of geranylgeranylation and Rho proteins. Circ Res.1998; 83:683–690.CrossrefMedlineGoogle Scholar9 Laufs U, Marra D, Node K, Liao JK. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). J Biol Chem.1999; 274:21926–21931.CrossrefMedlineGoogle Scholar10 Guijarro C, Blanco-Colio LM, Ortego M, Alonso C, Ortiz A, Plaza JJ, Diaz C, Hernandez G, Edigo J. 3-Hydroxy-3-methylglutaryl coenzyme A reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res.1998; 83:490–500.CrossrefMedlineGoogle Scholar11 Romano M, Diomede L, Sironi M, Massimiliano L, Sottocorno M, Polentarutti N, Guglielmotti A, Albani D, Bruno A, Fruscella P, Salmona M, Vecchi A, Pinza M, Mantovani A. Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest.2000; 80:1095–1100.CrossrefMedlineGoogle Scholar12 Casey PJ. Protein lipidation in cell signaling. Science.1995; 268:221–225.CrossrefMedlineGoogle Scholar13 Liu L, Moesner P, Kovach NL, Bailey R, Hamilton AD, Sebti SM, Harlan JM. Integrin-dependent leukocyte adhesion involves geranylgeranylated protein(s). J Biol Chem.1999; 274:33334–33340.CrossrefMedlineGoogle Scholar14 Libby P, Schoenbeck U, Mach F, Selwyn AP, Ganz P. Current concepts in cardiovascular pathology: the role of LDL cholesterol in plaque rupture and stabilization. Am J Med. 1998;104(2A):14S–18S.Google Scholar15 Liao F, Andalibi A, Qiao JH, Allayee H, Fogelman AM, Lusis AJ. Genetic evidence for a common pathway mediating oxidative stress, inflammatory gene induction, and aortic fatty streak formation in mice. J Clin Invest.1994; 94:877–884.CrossrefMedlineGoogle Scholar16 Napoli C, Quehenberger O, de Nigris F, Abete P, Glass CK, Palinski W. Apoptosis induced by mildly oxidized LDL involves multiple apoptotic signaling pathways in human coronary cells. FASEB J.2000; 14:1996–2007.CrossrefMedlineGoogle Scholar17 Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, Chia D, Terasaki PI, Sabad A, Cogert GA, Trosian K, Hamilton MA, Koriguchi JD, Kawata N, Hage A, Drinkwater DC, Stevenson LW. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med.1995; 333:621–627.CrossrefMedlineGoogle Scholar18 Wenke K, Meiser B, Thiery J, Nagel D, von Scheidt W, Steinbeck G, Seidel D, Reichart B. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation.1997; 96:1398–1402.LinkGoogle Scholar19 Bustos C, Hernández-Presa MA, Ortego M, Tuñón J, Ortega L, Pérez F, Díaz C, Hernández G, Egido J. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol.1998; 32:2057–2064.CrossrefMedlineGoogle Scholar20 Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E, for the Cholesterol and Recurrent Events (CARE) Investigators. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation.1999; 100:230–235.CrossrefMedlineGoogle Scholar21 Sparrow CP, Burton CA, Hernandez M, Mundt S, Hassing H, Patel S, Rosa R, Hermanowski-Vosatka A, Wang P-R, Zhang D, Peterson L, Detmers PA, Chao Y-S, Wright SD. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol.2001; 21:115–121.CrossrefMedlineGoogle Scholar22 Kita T, Brown MS, Goldstein JL. Feedback regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in livers of mice treated with mevinolin, a competitive inhibitor of the reductase. J Clin Invest.1980; 66:1094–1100.CrossrefMedlineGoogle Scholar23 Weber C, Erl W, Weber KS, Weber PC. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol.1997; 30:1212–1217.CrossrefMedlineGoogle Scholar24 Lefer AM, Campbell B, Shin YK, Scalia R, Hayward R, Lefer DJ. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation.1999; 100:178–184.CrossrefMedlineGoogle Scholar25 Pahan K, Sheikh FG, Namboodiri AM, Singh I. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest.1997; 100:2671–2679.CrossrefMedlineGoogle Scholar26 Stanislaus R, Pahan K, Singh AK, Singh I. Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin. Neurosci Lett.1999; 269:71–74.CrossrefMedlineGoogle Scholar27 Kothe H, Dalhoff K, Rupp J, Müller A, Kreuzer J, Maass M, Katus HA. Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae. Circulation.2000; 101:1760–1763.CrossrefMedlineGoogle Scholar28 Inoue I, Goto S, Mizotani K, Awata T, Mastunaga T, Kawai S, Nakajima T, Hokari S, Komoda T, Katayama S, Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of mRNA levels for interleukin-1β, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor-α (PPAR-α) in primary endothelial cells. Life Sci.2000; 67:863–876.CrossrefMedlineGoogle Scholar29 Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK. Peroxisome proliferator-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest.2000; 106:523–531.CrossrefMedlineGoogle Scholar30 Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunosuppressor. Nat Med.2000; 6:1399–1402.CrossrefMedlineGoogle Scholar31 Steimle V, Siegrist CA, Mottet A, Lisowska-Grospierre B, Mach B. Regulation of MHC class II expression by interferon-γ mediated by the transactivator gene CIITA. Science.1994; 265:106–109.CrossrefMedlineGoogle Scholar32 Palinski W. Immunomodulation: a new role for statins? Nat Med.2000; 6:1311–1312.CrossrefMedlineGoogle Scholar33 Palinski W, Witztum JL. Immune responses to oxidative neoepitopes on LDL and phospholipids modulate the development of atherosclerosis. J Intern Med.2000; 247:371–380.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Lin L, Yu T, Chang H, Tsai W and Pang J (2022) Simvastatin Downregulates Cofilin and Stathmin to Inhibit Skeletal Muscle Cells Migration, International Journal of Molecular Sciences, 10.3390/ijms23052848, 23:5, (2848) Linnenberger R, Hoppstädter J, Wrublewsky S, Ampofo E and Kiemer A (2021) Statins and Bempedoic Acid: Different Actions of Cholesterol Inhibitors on Macrophage Activation, International Journal of Molecular Sciences, 10.3390/ijms222212480, 22:22, (12480) Klein J, Mauck L, Schackert G and Pinzer T (2021) Do statins reduce the rate of revision surgery after chronic subdural hematoma drain?, Acta Neurochirurgica, 10.1007/s00701-021-04871-7, 163:7, (1843-1848), Online publication date: 1-Jul-2021. Chen Q, Shi X, Tang Y, Wang B, Xie H, Shi W and Li J (2020) Association between rosacea and cardiometabolic disease: A systematic review and meta-analysis, Journal of the American Academy of Dermatology, 10.1016/j.jaad.2020.04.113, 83:5, (1331-1340), Online publication date: 1-Nov-2020. Sultan F, Kaur R, Mir A, Maqbool I, Lonare M, Singh D, Rampal S and Dar J (2020) Rosuvastatin and retinoic acid may act as 'pleiotropic agents' against β-adrenergic agonist-induced acute myocardial injury through modulation of multiple signalling pathways, Chemico-Biological Interactions, 10.1016/j.cbi.2020.108970, 318, (108970), Online publication date: 1-Feb-2020. Orban E, Fechete R and Şipoş R (2020) The osteoprotective effect of simvastatin from the perspective of VIS-nearIR spectrometric studies, Medic.ro, 10.26416/Med.134.2.2020.3116, 2:134, (21), . Oh M, Kim H, Shin E, Sung C, Kim D, Moon D and Lee C (2019) Effects of ezetimibe/simvastatin 10/10 mg versus Rosuvastatin 10 mg on carotid atherosclerotic plaque inflammation, BMC Cardiovascular Disorders, 10.1186/s12872-019-1184-2, 19:1, Online publication date: 1-Dec-2019. Solberg O, Stavem K, Ragnarsson A, Beitnes J, Skårdal R, Seljeflot I, Ueland T, Aukrust P, Gullestad L and Aaberge L (2019) Index of microvascular resistance to assess the effect of rosuvastatin on microvascular function in women with chest pain and no obstructive coronary artery disease: A double‐blind randomized study, Catheterization and Cardiovascular Interventions, 10.1002/ccd.28157, 94:5, (660-668), Online publication date: 1-Nov-2019. Nikolic Turnic T, Arsic A, Vucic V, Petrovic S, Ristic-Medic D, Zivkovic V, Srejovic I, Jeremic J, Radonjic T, Milosavljevic I, Bolevich S, Bolevich S, Djuric D and Jakovljevic V (2019) Hydroxymethylglutaryl Coenzyme a Reductase Inhibitors Differentially Modulate Plasma Fatty Acids in Rats With Diet-Induced-Hyperhomocysteinemia: Is ω-3 Fatty Acids Supplementation Necessary?, Frontiers in Physiology, 10.3389/fphys.2019.00892, 10 Vieira G, Cavalli J, Gonçalves E, Gonçalves T, Laurindo L, Cola M and Dutra R (2017) Effects of Simvastatin Beyond Dyslipidemia: Exploring Its Antinociceptive Action in an Animal Model of Complex Regional Pain Syndrome-Type I, Frontiers in Pharmacology, 10.3389/fphar.2017.00584, 8 Henninger C and Fritz G (2017) Statins in anthracycline-induced cardiotoxicity: Rac and Rho, and the heartbreakers, Cell Death & Disease, 10.1038/cddis.2016.418, 8:1, (e2564-e2564) Rohilla A, Rohilla S, Kumar A, Khan M and Deep A (2016) Pleiotropic effects of statins: A boulevard to cardioprotection, Arabian Journal of Chemistry, 10.1016/j.arabjc.2011.06.025, 9, (S21-S27), Online publication date: 1-Sep-2016. Kocak F, Kucuk A, Ozyigit F, Tosun M, Kocak C, Kocak A, Ekici M, Yaylak F and Genc O (2015) Protective effects of simvastatin administered in the experimental hepatic ischemia-reperfusion injury rat model, Journal of Surgical Research, 10.1016/j.jss.2015.06.009, 199:2, (393-401), Online publication date: 1-Dec-2015. Zhao J, Natarajan S, Chronos N and Singh J Cerivastatin represses atherogenic gene expression through the induction of KLF2 via isoprenoid metabolic pathways, Cellular and Molecular Biology Letters, 10.1515/cmble-2015-0049, 20:5 Snowden S, Grapov D, Settergren M, D'Alexandri F, Haeggström J, Fiehn O, Hyötyläinen T, Pedersen T, Newman J, Orešič M, Pernow J and Wheelock C (2014) High-Dose Simvastatin Exhibits Enhanced Lipid-Lowering Effects Relative to Simvastatin/Ezetimibe Combination Therapy, Circulation: Cardiovascular Genetics, 7:6, (955-964), Online publication date: 1-Dec-2014. António N, Soares A, Fernandes R, Soares F, Lopes A, Carvalheiro T, Paiva A, Providência L, Gonçalves L and Fontes Ribeiro C (2014) Endothelial progenitor cells in diabetic patients with myocardial infarction – Can statins improve their function?, European Journal of Pharmacology, 10.1016/j.ejphar.2014.07.010, 741, (25-36), Online publication date: 1-Oct-2014. Iwase H, Ezzelarab M, Ekser B and Cooper D (2014) The role of platelets in coagulation dysfunction in xenotransplantation, and therapeutic options, Xenotransplantation, 10.1111/xen.12085, 21:3, (201-220), Online publication date: 1-May-2014. Okano A, Oya S, Fujisawa N, Tsuchiya T, Indo M, Nakamura T, Chang H and Matsui T (2013) Analysis of risk factors for chronic subdural haematoma recurrence after burr hole surgery: Optimal management of patients on antiplatelet therapy, British Journal of Neurosurgery, 10.3109/02688697.2013.829563, 28:2, (204-208), Online publication date: 1-Apr-2014. Adam O and Laufs U (2014) Rac1-Mediated Effects of HMG-CoA Reductase Inhibitors (Statins) in Cardiovascular Disease, Antioxidants & Redox Signaling, 10.1089/ars.2013.5526, 20:8, (1238-1250), Online publication date: 10-Mar-2014. Sawada N and Liao J (2014) Rho/Rho-Associated Coiled-Coil Forming Kinase Pathway as Therapeutic Targets for Statins in Atherosclerosis, Antioxidants & Redox Signaling, 10.1089/ars.2013.5524, 20:8, (1251-1267), Online publication date: 10-Mar-2014. Moazzami K, Emamzadeh-Fard S and Shabani M (2012) Anticonvulsive effect of atorvastatin on pentylenetetrazole-induced seizures in mice: the role of nitric oxide pathway, Fundamental & Clinical Pharmacology, 10.1111/j.1472-8206.2012.01038.x, 27:4, (387-392), Online publication date: 1-Aug-2013. Chacko J, Harling L, Ashrafian H and Athanasiou T (2013) Can Statins Improve Outcomes After Isolated Cardiac Valve Surgery? A Systematic Literature Review, Clinical Cardiology, 10.1002/clc.22140, 36:8, (448-455), Online publication date: 1-Aug-2013. Grigore L, Raselli S, Garlaschelli K, Redaelli L, Norata G, Pirillo A and Catapano A (2012) Effect of treatment with pravastatin or ezetimibe on endothelial function in patients with moderate hypercholesterolemia, European Journal of Clinical Pharmacology, 10.1007/s00228-012-1345-z, 69:3, (341-346), Online publication date: 1-Mar-2013. Matsumura T, Taketa K, Shimoda S and Araki E (2011) Thiazolidinedione-independent activation of peroxisome proliferator-activated receptor γ is a potential target for diabetic macrovascular complications, Journal of Diabetes Investigation, 10.1111/j.2040-1124.2011.00182.x, 3:1, (11-23), Online publication date: 1-Feb-2012. Giga V, Lepojević D, Beleslin B, Đorđević-Dikić A, Komnenović S, Stepanović J, Vasiljević Z and Ostojić M (2012) The effects of early statin therapy on endothelial function in patients with acute myocardial infarction: A randomized study, Srce i krvni sudovi, 10.5937/siks1202077G, 31:4, (77-81), . Maria Grazia Z and Claudia S (2011) Effects of selective H.E.L.P. LDL-apheresis on plasma inflammatory markers concentration in severe dyslipidemia: Implication for anti-inflammatory response, Cytokine, 10.1016/j.cyto.2011.08.038, 56:3, (850-854), Online publication date: 1-Dec-2011. Skogastierna C, Luksha L, Kublickiene K, Eliasson E, Rane A and Ekström L (2011) Beneficial vasoactive endothelial effects of fluvastatin: focus on prostacyclin and nitric oxide, Heart and Vessels, 10.1007/s00380-010-0097-x, 26:6, (628-636), Online publication date: 1-Nov-2011. Rosendo A, Lima L, Dal-Pizzol F and Almeida S (2010) Lipid and C-Reactive Protein Levels, Cardiovascular Disease Risk Factors and Simvastatin Treatment in Brazilian Individuals, Inflammation, 10.1007/s10753-009-9178-3, 33:4, (244-250), Online publication date: 1-Aug-2010. Zhou Q and Liao J (2010) Pleiotropic Effects of Statins - Basic Research and Clinical Perspectives -, Circulation Journal, 10.1253/circj.CJ-10-0110, 74:5, (818-826), . Dobler C, Wong K and Marks G (2009) Associations between statins and COPD: a systematic review, BMC Pulmonary Medicine, 10.1186/1471-2466-9-32, 9:1, Online publication date: 1-Dec-2009. Settergren M, Böhm F, Rydén L, Pernow J and Kalani M (2009) Lipid lowering versus pleiotropic effects of statins on skin microvascular function in patients with dysglycaemia and coronary artery disease, Journal of Internal Medicine, 10.1111/j.1365-2796.2009.02128.x, 266:5, (492-498), Online publication date: 1-Nov-2009. Chow S (2009) Immunomodulation by statins: mechanisms and potential impact on autoimmune diseases, Archivum Immunologiae et Therapiae Experimentalis, 10.1007/s00005-009-0038-5, 57:4, (243-251), Online publication date: 1-Aug-2009. Pérez V, Navarro-Muñoz M, Bayés B, Lauzurica R, Pastor M, Troya M, Bonet J, Ibernón M, Navarro M, Serra A, Núñez A and Romero R (2009) Effect of Low Doses of Atorvastatin on the Urinary Peptide Profile of Kidney Transplant Patients, Transplantation Proceedings, 10.1016/j.transproceed.2009.06.170, 41:6, (2111-2114), Online publication date: 1-Jul-2009. Lin C, Cooper D and Dorling A (2009) Coagulation dysregulation as a barrier to xenotransplantation in the primate, Transplant Immunology, 10.1016/j.trim.2008.10.008, 21:2, (75-80), Online publication date: 1-Jun-2009. Nagassaki S, Herculano R, Graeff C and Tanus-Santos J (2008) eNOS T-786C polymorphism affects atorvastatin-induced changes in erythrocyte membrane fluidity, European Journal of Clinical Pharmacology, 10.1007/s00228-008-0602-7, 65:4, (385-392), Online publication date: 1-Apr-2009. Chatterjee T, Macdonald A and Waters H (2011) A Model for Ischaemic Heart Disease and Stroke III: Applications, Annals of Actuarial Science, 10.1017/S1748499500000476, 3:1-2, (105-119), Online publication date: 1-Sep-2008. Chatterjee T, Macdonald A and Waters H (2011) A Model for Ischaemic Heart Disease and Stroke II: Modelling Obesity, Annals of Actuarial Science, 10.1017/S1748499500000464, 3:1-2, (83-103), Online publication date: 1-Sep-2008. Chatterjee T, Macdonald A and Waters H (2011) A Model for Ischaemic Heart Disease and Stroke I: The Model, Annals of Actuarial Science, 10.1017/S1748499500000452, 3:1-2, (45-81), Online publication date: 1-Sep-2008. Settergren M, Bohm F, Ryden L and Pernow J (2008) Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease, European Heart Journal, 10.1093/eurheartj/ehn166, 29:14, (1753-1760) van de Garde E (2008) Statines ter preventie van pneumonie, Huisarts en Wetenschap, 10.1007/BF03086725, 51:4, (195-197), Online publication date: 1-Apr-2008. Seo M, Inoue I, Ikeda M, Nakano T, Takahashi S, Katayama S and Komoda T (2008) Statins Activate Human PPAR Promoter and Increase PPAR mRNA Expression and Activation in HepG2 Cells, PPAR Research, 10.1155/2008/316306, 2008, (1-11
Referência(s)